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A B S T R A C T
Objective: To use Multi-Criteria Decision Analysis (MCDA) to determine weights for eleven criteria in
order to prioritize COVID-19 non-critical patients for admission to hospital in healthcare settings with
limited resources.
Methods: The MCDA was applied in two main steps: specification of criteria for prioritizing COVID-19
patients (and levels within each criterion); and determination of weights for the criteria based on
experts’ knowledge and experience in managing COVID-19 patients, via an online survey. Criteria were
selected based on available COVID-19 evidence with a focus on low- and middle-income countries
(LMICs).
Results: The most important criteria (mean weights, summing to 100%) are: PaO2 (16.3%); peripheral O2
saturation (15.9%); chest X-ray (14.1%); Modified Early Warning Score-MEWS (11.4%); respiratory rate
(9.5%); comorbidities (6.5%); living with vulnerable people (6.4%); body mass index (5.6%); duration of
symptoms before hospital evaluation (5.4%); CRP (5.1%); and age (3.8%).
Conclusions: At the beginning of a new pandemic, when evidence for disease predictors is limited or
unavailable and effective national contingency plans are difficult to establish, the MCDA prioritization
model could play a pivotal role in improving the response of health systems.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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As of 13th May 2020, there have been 4,170,424 confirmed cases
and 287,399 confirmed deaths from SARS CoV-2 worldwide (World
Health Organization. COVID-19 disease pandemic, 2020). Since the
first case of the coronavirus disease 2019 (COVID-19) was recorded* Corresponding author at: Division of Infectious Diseases, Department of
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eleonora.cremonini@univr.it (E. Cremonini), paul.hansen@otago.ac.nz (P. Hansen),
herman.goossens@uza.be (H. Goossens), evelina.tacconelli@univr.it (E. Tacconelli).
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1201-9712/© 2020 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).in Italy on 21st February, 2,735,628 nasopharyngeal swabs have
been processed. The number of cases and deaths has reached
222,104 and 31,106 respectively, with Italy having one of the
highest national rates of local transmission. The Italian govern-
ment imposed aggressive measures to contain the spread of the
disease. Nevertheless, the daily incidence of new COVID-19 cases
and deaths reached alarming rates (Ministero della Salute. COVID-
19 Situazione in Italia, 2020). SARS CoV-2 appeared in Italy in the
middle of flu season, contributing to the over-crowding of primary
care, outpatient clinics and emergency departments. Due to the
COVID-19 pandemic emergency, the Italian National Health
System (NHS), which is regionally based and offers universal
access to healthcare, has been close to collapse (Armocida et al.,
2020). The shortage of available hospital beds and the lack of beds
in intensive care units (ICUs) for critically ill patients have been
among the major challenges faced.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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strong economies can be rapidly overwhelmed by this emergency,
attention starts to be focused on less advantaged areas of the world
(Hopman et al., 2020). In low- and middle-income countries
(LMICs), where over-crowding renders social distancing almost
impossible, shortages of hand sanitizers and clean water are the
norm and prevention measures are difficult to establish, the spread
of the pandemic could have catastrophic consequences. Healthcare
facilities, already congested and lacking personnel and supplies,
are likely to be rapidly overwhelmed and not able to provide
potentially life-saving services – such as caesarean sections or
basic surgery – anymore (Bong et al., 2020). An African task force
for coronavirus preparedness and response (AFTCOR) has been
established, focusing on: laboratory diagnosis and subtyping,
surveillance, infection prevention and control in health care
facilities, clinical treatment of people with severe COVID-19, risk
communication, and supply chain management (Nkengasong et
Mankoula, 2020). Nonetheless, prioritizing access to care in
settings at extremely high risk of collapse appears to be
unavoidable.
Unlike triage for prioritizing admissions to ICUs – which has
been debated worldwide (Emanuel et al., 2020; White and Lo,
2020; The Hastings Center, 2020) – no explicit recommendations
have been developed to identify which COVID-19 patients are
prioritized for hospital admission in settings with an unsolvable
shortage of beds and in LMICs. The quality of such prioritization
decision-making when multiple criteria need to be considered
together can be improved by using structured and explicit
methods. Multi-Criteria Decision Analysis (MCDA) is useful in
such a context. Fundamental to MCDA is specifying the criteria that
are relevant for the decision at hand and determining their relative
importance (usually represented in terms of weights). Widely used
in many sectors, MCDA is increasingly employed in healthcare
applications to increase the consistency, transparency, and
legitimacy of decisions (Thokala et al., 2016; Marsh et al., 2014).
The objective of this study was to use MCDA to identify non-
critical COVID-19 patients who should be admitted to hospital
because of their risk of rapid clinical deterioration.
Methods
MCDA and the PAPRIKA method
The MCDA was applied in two main steps: 1. specification of
criteria for prioritizing COVID-19 patients for hospitalization and
the levels within each criterion, and 2. determination of weights
for the criteria (and their levels), representing their relative
importance, based on experts’ knowledge and preferences. At the
first step, evidence from the scientific literature on predictors of
outcomes in patients affected by COVID-19 was reviewed up to
March 15. At the second step, a large group of Italian experts were
invited to complete an online survey to determine the weights for
the criteria. The experts were selected according to their
experience in dealing with COVID-19 patients, and included
physicians based in emergency, infectious diseases, pneumology,
and internal medicine departments and working in a variety of
institutions (i.e. university hospitals, institutes for research and
treatment, and community hospitals). Attention was paid to the
prevalence of COVID-19 cases in the experts’ region: more experts
based in northern Italian regions were invited than experts in
southern regions where the disease is less prevalent.
The survey was run using 1000minds MCDA software
(www.1000minds.com) which implements the PAPRIKA (Poten-
tially All Pairwise RanKings of all possible Alternatives) method
(Hansen and Ombler, 2008). Previous applications of the software
and method include prioritizing patients for elective surgery andcreating the World Health Organization’s priority list of antibiotic-
resistant bacteria to support research and development of new
drugs (Hansen et al., 2012; Tacconelli et al., 2018). The PAPRIKA
method involved each participant being shown a series of pairs of
combinations of levels on two criteria at a time (in effect,
representing a pair of imaginary patients) and asked for each pair:
“Which one of these combinations of criteria is more relevant for the
hospitalization of a COVID-19 patient during a health emergency,
considering a shortage of hospital beds?”. Each pair of combinations
involved a trade-off between the two criteria, such that when
participants answered the question – by choosing one of the two
combinations or indicating they are equal – they revealed their
opinion about the relative importance of the two criteria. Such
questions (always involving a trade-off between the criteria, two at
a time) were repeated with different combinations of the criteria
until enough information was collected to determine each
participant’s set of weights for the criteria (using mathematical
methods based on linear programming) (Hansen and Ombler,
2008). The criteria were not disclosed to the experts before the
survey in order not to influence their answers. Two questions were
repeated at the end of the survey as an internal consistency check.
The software recorded the number of questions answered and the
time taken to answer each question. At the end of the survey, the
experts were also asked for their opinion about the usefulness of
lung ultrasound (US) compared to chest X-ray for diagnosing
COVID-19 pneumonia.
Participants’ weights were averaged to produce mean weights
(and standard deviations, SD) for the group of experts as a whole.
Significant differences in the mean weights for the criteria
(p < 0,05) were assessed through a one-way analysis of variance
for normally distributed variables, and the Kruskal-Wallis rank test
when the normality assumption was not met.
Role of the funding source
The funders of the study had no role in study design, data
collection, data analysis, data interpretation, writing of the
article, or the decision to submit for publication. All authors
were responsible for the decision to submit the article for
publication.
Results
A board of five Infectious Diseases (ID) physicians with
experience in treating COVID-19 patients selected 11 criteria to
prioritize hospital admission, based on the current evidence and
the availability and feasibility of criteria in LMICs (Zhang et al.,
2020; Chen et al., 2020; Wang et al., 2020; Guan et al., 2020; Mo
et al., 2020). The criteria (levels in parentheses) were: 1. age (18–
50, 50–70, and >70); 2. body mass index (BMI: <30, 30–40, and
>40); 3. Co morbidities (diabetes, pre-existing respiratory/
cardiovascular diseases, and onco-hematological diseases); 4.
respiratory rate (<20 breaths/min and >20 breaths/min); 5.
PaO2 (>80 mmHg, 70–80 mmHg, and <70 mmHg); 6. peripheral
oxygen (O2) saturation (>96%, 92–96%, and <92%); 7. findings at
chest X-ray (normal, consolidation, and bilateral interstitial lung
abnormalities); 8. Modified Early Warning Score-MEWS (Subbe
et al., 2001), a clinical scoring system including pulse rate,
respiratory rate, systolic blood pressure, body temperature, and
neurological symptoms (score: 0–2 and 3–4); 9. duration of
symptoms before hospital evaluation (<3 days, 4–7 days, and >7
days); 10. C-reactive protein (CRP: normal / high by local cut off);
and 11. living with vulnerable people (i.e. people with comorbid-
ities, pregnant women, or immunosuppressed patients). CRP was
selected considering its potential availability as a point-of-care
(POC) test worldwide (Drain et al., 2014).
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the criteria weights ran for 15 days and was completed by 103
experts. Of them, 96 (93%) answered the two repeated questions
consistently and were therefore included in the final analysis.
These 96 experts were from 11 Italian regions, with the majority
(70%) from Lombardy, Piedmont and Veneto, the three regions in
northern Italy with the highest burden of cases. Fifty-three percent
of the experts were working at institutions dealing with more thanFigure 1. Mean weights for the criteria
The bolded values represent the relative weights of the criteria overall (i.e. the bolded
Abbreviations: MEWSmodified early warning score; “comorbidities” criterion includes:
diseases; “living with vulnerable people” criterion includes: people with comorbidities500 COVID-19 patients since the beginning of the pandemic; 32%
were based at university hospitals and 20% at institutes for
research and treatment; 77% were ID physicians; and 53% were
female. The mean number of questions answered by each
participant was 36 (IQR 12), taking most participants 10–15 min
in total.
From the experts’ answers to the survey, the most important
criterion [mean weights, summing to 100%] was revealed to be values sum to 100%).
 diabetespre-existing respiratory/cardiovascular diseases, and onco-hematological
and/or pregnant women, and/or immunosuppressed patients.
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ray [14.1%], MEWS [11.4%], respiratory rate [9.5%], comorbidities
[6.5%], living with vulnerable people [6.4%], BMI [5.6%], duration of
symptoms before hospital evaluation [5.4%], CRP [5.1%], and age
[3.8%]. The criteria and their levels and mean weights are reported
in Figure 1. The values for each criterion’s highest level (bolded in
the figure) sum across the criteria to one (100%), and thus each of
these values is easily interpretable as the attribute’s relative weight
overall. The value assigned to any middle levels of a criterion
represents the combined effect of the level’s relative position on
the particular criterion as well as the criterion’s weight; and each
criterion’s lowest level has a value of zero. For any pair of criteria,
the ratio of their overall weights measures their relative
importance; for example, MEWS (Subbe et al., 2001) was 1.2
times (e.g. 11.4%/9.5%) more important than tachypnoea alone
(respiratory rate >20 breaths/min) and approximately twice as
important as duration of symptoms, C-reactive protein and BMI
respectively (Figure 2). The majority of experts (70%) indicated that
they think lung-US is more valuable than chest X-ray as an imaging
tool for evaluating COVID-19 patients. The table presents an
example of applying the mean weights to 10 randomly selected
COVID-19 patients attending the emergency department from 1st
March 2020 at the Verona University Hospital. More in detail,Figure 2. Relative importance of the criteria
Based on the mean weights, each number in the figure is a ratio corresponding to the 
reported too, faded). The ratios are obtained by dividing the left weights by the top weigh
of symptoms is 1.5 times more important than age, etc.). Abbreviations: MEWS, modified 
criterion includes: diabetes, pre-existing respiratory/cardiovascular diseases, and onco-
with comorbidities, and/or pregnant women, and/or immunosuppressed patients.patients with a total score <33% were not admitted to inpatient
COVID-19 unit. At follow-up they had no adverse outcome in terms
of need of hospitalization, and/or need of oxygen therapy and/or
death. Patients ranked 47% were all admitted (data not shown in
the table). These patients needed high-flow oxygen therapy or
non-invasive ventilation during inpatient stay (Table 1).
Discussion
The criteria included in the MCDA prioritization model
developed here were deliberately selected in order to be able to
be applied ‘anywhere and by anyone’, including by unskilled health
personnel and in low-resource settings. This approach was
intended to meet the needs of LMICs where, due to very limited
resources, effective national contingency plans are difficult to
establish.
At early stage, mild hypoxemia due to an impaired gas exchange
can be easily identified using an arterial blood gas test (ABGT).
Accordingly, PaO2 was the most important criterion identified by
the experts. The second most important criterion, with a similar
weight, was peripheral O2 saturation – suggesting that in settings
where ABGT is unavailable, such as LMICs or even during domestic
self-isolation, pulse oximetry may be a useful alternative to moreimportance of the criterion on the left relative to the criterion at the top (weights
ts (i.e.: MEWS score is 2 times more important than duration of symptoms; duration
early warning score; BMI, body mass index; CRP, C-reactive protein; “comorbidities”
hematological diseases; “living with vulnerable people” criterion includes: people
Table 1
Application of the weights to 10 COVID-19 randomly selected patients attending the emergency room from the 1st March 2020 at Verona University Hospital, Italy. Total
scores are calculated by summing the weights for each patient according to the patient’s rating on the levels for the criteria.
Rank Age
range













1 >70 Yes <30 >7 >20 <92 Ne interstitial lung
abnormalities
No 0–2 65–70 69
2 18–50 Yes >40 <3 >20 92–96 N N No 3–4 65–70 54
3 18–50 No 31–
40
>7 >20 92–96 Hf pulmonary
consolidation
No 3–4 71–80 54
4 51–70 No <30 4–7 >20 92-96 H N No 3–4 71–80 50
5 51–70 No <30 4–7 <20 92–96 H N Yes 3–4 71–80 47
6 51–70 No <30 4–7 <20 >96 N interstitial lung
abnormalities
No 0–2 71–80 32
7 18–50 No <30 <3 >20 >96 N N Yes 3–4 >80 25
8 18–50 Yes >40 >7 <20 >96 N pulmonary
consolidation
No 0–2 >80 23
9 >70 No <30 4–7 <20 >96 N N No 3–4 >80 22
10 >70 Yes <30 >7 <20 >96 N N No 0–2 >80 15
a Body Mass Index;
b peripheral oxygen saturation;
c C-reactive protein;
d Modified Early Warning score;
e Normal;
f High.
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probably because of the lower accuracy especially at an early phase
of the disease. Indeed, a ‘normal’ chest radiograph should not
exclude the possibility that an interstitial disorder is present in the
appropriate clinical context (Ryu et al., 2007). The use of lung-US
for evaluating COVID-19 patients has several advantages – such as
lower risk of exposure to healthcare workers, repeatability during
follow-up and lower costs and easier application, especially in
LMICs (Soldati et al., 2020a). Moreover, lung-US can be applied in
outpatient settings, as a triage for symptomatic patients at home as
well as in the prehospital phase (Soldati et al., 2020b).
MEWS is a score that uses readily available and inexpensive
clinical parameters to identify patients at increased risk of ICU
admission or death (Subbe et al., 2001). With respect to the criteria’
ranking, MEWS score was considerably less important than PaO2
and O2 saturation. Moreover, MEWS was only 1.2 times more
important than tachypnoea alone, corroborating the importance of
parameters related to the respiratory system (O2 saturation and
respiratory rate) outlined by this analysis. MEWS can be obtained
quickly by physical examination and also by unskilled healthcare
workers, and it has the advantage of combining both respiratory
and non-respiratory parameters to assess a possible rapid
worsening of clinical conditions – making it the fourth most
important criterion.
Although it is well known that age negatively affects the
outcome in COVID-19 patients (Li et al., 2020), age was found to be
the least-important criterion. Remarkably, both BMI and CRP were
1.5 and 1.3 times more important than age, respectively. As
recently published by Zhang et al. (2020), CRP testing could be used
at the point of care in order to direct patients further along the
treatment path. Finally, living with vulnerable people was also
deemed to be a relevant criterion to consider when deciding
whether to admit a COVID-19 patient, even though it is not a
clinical parameter.
According to experts’ evaluation of COVID-19 patients, all ages
are potentially at risk of rapid clinical deterioration. Although PaO2
– or alternatively O2 saturation – are essential parameters, both
MEWS and BMI should be considered to predict negative clinical
outcome and not deferrable need of hospitalization. Finally, in case
of a large volume of patients entering healthcare facilities, POC CRPtesting can be adopted as a useful criterion in the proposed
prioritization model.
To the best of the authors’ knowledge, this is the first time that
MCDA has been used in a pandemic event for ranking non-critical
patients for hospitalization. Since most of the criteria can be
collected also by patients themselves, a “simplified domestic
model” for patients self-isolated would be easily adapted by
excluding some criteria (e.g. chest X-ray and ABGT) and including
others like peripheral O2 saturation. This approach represents an
innovative way of coordinating efforts during a pandemic caused
by a novel virus. Determining criteria and weights for prioritizing
patients is even more relevant in conditions of critical imbalance
between need and available resources. Furthermore, this model
(criteria and weights) can be adapted to different settings and
stages of the pandemic in response to emerging evidence. In the
demonstrative case series shown in the table, for example, a
threshold above 33% may be proposed for the identification of
patients to be hospitalized, as all the patients ranked below this
cut-off did not need hospitalization and had an overall positive
outcome. The most adequate method to validate a threshold
definition would be that of applying MCDA results to a cohort
study. At the beginning of a new pandemic, it may be feasible to
prospectively gather patients’ information based on the MCDA
prioritization model (possibly with a multicentric approach). In
this way, a threshold to support clinical decisions could be quickly
available. Future research could include the validation of the
patients’ scores also through machine learning. The results of this
study suggest that, when evidence is limited, using MCDA to codify
experts’ knowledge is a rapid and effective approach for creating
tools to support difficult decision-making.
Contributors
PDN and EG conceived the study and wrote the first draft of the
manuscript. FM and EC reviewed the literature. PH worked on the
statistical analysis and revised the manuscript. HG and ET critically
revised the manuscript. Each member of the COVID-19 MCDA
Group was involved in the survey and contributed significantly to
the work. All authors have seen and approved the final manuscript
and contributed significantly to the work.
P. De Nardo et al. / International Journal of Infectious Diseases 98 (2020) 494–500 499Funding
The Value-Dx project was supported by the Innovative
Medicines Initiative 2 Joint Undertaking under grant agreement
No 820755. This Joint Undertaking receives support from the
European Union’s Horizon 2020 research and innovation program
and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV,
Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD
Switzerland Sàrl, and The Wellcome Trust Limited.
Ethical approval
Approval was not required.
Declaration of interests
The authors declare that they have no competing interests.
Acknowledgments
We would like to thank all the colleagues who participated in
the survey. Sincere thanks also to 1000minds Ltd based in New
Zealand for making 1000minds software available for free.
The authors dedicate this work to all healthcare workers who
lost their lives in the fight against COVID-19 pandemic.
Appendix A.
Members of the COVID-19 MCDA Group include:
E. Durante Mangoni, L. L. Florio, R. Zampino, F. Mele (Internal
Medicine, University of Campania “Luigi Vanvitelli” and AORN
Ospedali dei Colli – Monaldi Hospital, Naples, Italy); I. Gentile, B.
Pinchera (Department of Clinical Medicine and Surgery – Section of
Infectious Diseases – University of Naples Federico II”, Naples,
Italy); N. Coppola, M. Pisaturo (University of Campania, Infectious
Diseases Unit, AORN Sant’Anna e San Sebastiano di Caserta,
Caserta, Italy); R. Luzzati (Dept. Haematology, Oncology &
Infectious Diseases, University of Trieste Ospedale Maggiore,
Trieste, Italy); N. Petrosillo, E. Nicastri, A. Corpolongo, M. A.
Cataldo, A. D’Abramo, G. Maffongelli, L. Scorzolini, C. Palazzolo, E.
Boumis (Clinical and Research Department, National Institute for
Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy); A. Pan
(Infectious Diseases Unit, ASST Cremona, Cremona, Italy); A.
D’Arminio Monforte, F. Bai (Institute of Infectious and Tropical
Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo,
University of Milan, Italy); S. Antinori (III Division of Infectious
Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan,
Italy); F. G. De Rosa, S. Corcione, T. Lupia, S. M. Pinna, S. Scabini, F.
Canta, S. Belloro (Department of Medical Sciences, Infectious
Diseases at Amedeo di Savoia Hospital, University of Turin, Turin,
Italy); Z. Bisoffi, A. Angheben, F. Gobbi, E. Turcato, N. Ronzoni, L.
Moro, S. Calabria, P. Rodari, G. Bertoli, G. Marasca (Department of
Infectious - Tropical Diseases and Microbiology, IRCCS Ospedale
Sacro Cuore Don Calabria, Negrar di Valpolicella, Italy); M. Puoti
(Infectious Diseases Unit, AO Ospedale Niguarda Ca’ Granda, Milan,
Italy); A. Gori, A. Bandera, D. Mangioni (Infectious Diseases Unit,
Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico.
Centre for Multidisciplinary Research in Health Science (MACH),
University of Milan); M. Rizzi (Infectious Diseases Unit, ASST Papa
Giovanni XXIII, Bergamo, Italy); F. Castelli (University Department
of Infectious and Tropical Diseases, University of Brescia and ASST
Spedali civili di Brescia, Brescia, Italy); A. Montineri, C. A. Coco, M.
Maresca, M. Frasca (Unit of Infectious Diseases and Hepatology,
Policlinico-Vittorio Emanuele, University Hospital Complex
(Azienda Ospedaliero Universitaria ‘Policlinico-Vittorio Ema-
nuele’), University of Catania, Catania, Italy); D. Aquilini (InfectiousDiseases Unit, Nuovo Ospedale S. Stefano, Prato, Italy); M. Vincenzi
(Infectious Diseases Unit, Mater Salutis Hospital, Legnago, Italy); L.
Lambertenghi, M. E. De Rui, E. Razzaboni, P. Cattaneo, A. Visentin, A.
Erbogasto, I. Dalla Vecchia, I. Coledan, M. Vecchi, G. Be, L. Motta, A.
Zaffagnini, N. Auerbach, P. Del Bravo, A. M. Azzini, E. Righi, E.
Carrara, A. Savoldi, M. Sibani, E. Lattuada, G. Carolo, M. Cordioli, F.
Soldani, M. D. Pezzani, S. Avallone (Infectious Diseases Unit,
Department of Diagnostics and Public Health, Verona University
Hospital, Verona, Italy); R. Bruno, A. Ricciardi (Infectious Diseases
Unit, IRCCS “San Matteo”, Pavia, Italy; Department of Medical,
Surgical, Diagnostic and Paediatric Science, University of Pavia,
Pavia, Italy); M. P. Saggese Emergency Department, “Santo Spirito”
Hospital, ASL Roma 1, Rome, Italy); G. Malerba (Department of
Internal Medicine, Ivrea Hospital, Turin, Italy).
References
Armocida B, Formenti B, Ussai S, Palestra F, Missoni E. The Italian health system and
the COVID-19 challenge. Lancet Public Health 2020; S2468-2667(20)30074-
30078.
Bong CL, Brasher C, Chikumba E, McDougall R, Mellin-Olsen J, Enright A. The COVID-
19 pandemic: effects on low and middle-income Countries [published online
ahead of print, 2020 Apr1]. Anesth Analg 2020;, doi:http://dx.doi.org/10.1213/
ANE.0000000000004846.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
China: a descriptive study. Lancet 2020;395(10223):507–13.
Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al. Diagnostic
point-of-care tests in resource-limited settings. Lancet Infect Dis 2014;14
(3):239–49.
Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation
of scarce medical resources in the time of Covid-19 [Epub ahead of print]. N Engl
J Med 2020;, doi:http://dx.doi.org/10.1056/NEJMsb2005114.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of
coronavirus disease 2019 in China, China medical treatment expert group for
covid-19 [Epub ahead of print]. N Engl J Med 2020;, doi:http://dx.doi.org/
10.1056/NEJMoa2002032.
Hansen P, Hendry A, Naden R, Ombler F, Stewart R. A new process for creating points
systems for prioritising patients for elective health services. Clin Governance:
Int J 2012;17:200–9.
Hansen P, Ombler F. A new method for scoring additive multi-attribute value
models using pairwise rankings of alternatives. J Multi-Criteria Dec Analysis
2008;15:87–107.
Hopman J, Allegranzi B, Mehtar S. Managing COVID-19 in Low- and Middle-Income
Countries [Published online, 2020 March 16]. JAMA 2020;, doi:http://dx.doi.
org/10.1001/jama.2020.4169.
Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19
inpatients in Wuhan [published online ahead of print, 2020 Apr 12]. J Allergy
Clin Immunol 2020;, doi:http://dx.doi.org/10.1016/j.jaci.2020.04.006 S0091-
6749(20)30495-4.
Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J. Assessing the value of healthcare
interventions using multi-criteria decision analysis: a review of the literature.
PharmacoEconomics 2014;32(4):345–65.
Ministero della Salute. COVID-19 Situazione in Italia. COVID-19 Situazione in Italia.
[cited 2020 May 13]. Available from:. 2020. http://www.salute.gov.it/portale/
nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?area=nuovoCoro-
navirus&id=5351&lingua=italiano&menu=vuoto.
Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of
refractory COVID-19 pneumonia in Wuhan, China [Epub ahead of print]. Clin
Infect Dis 2020;, doi:http://dx.doi.org/10.1093/cid/ciaa270 pii:ciaa270.
Nkengasong JN, Mankoula W. Looming threat of COVID-19 infection in Africa: act
collectively, and fast. Lancet 2020;395(10227):841–2.
Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. Mayo
Clin Proc 2007;82:976–86.
Soldati G, Smargiassi A, Inchingolo R, Buonsenso D, Perrone T, Briganti DF, et al.
Proposal for international standardization of the use of lung ultrasound for
patients with COVID-19: a simple, quantitative, reproducible method. J
Ultrasound Med 2020a;, doi:http://dx.doi.org/10.1002/jum.15285.
Soldati G, Smargiassi A, Inchingolo R, Buonsenso D, Perrone T, Briganti DF, et al. Is
there a role for lung ultrasound during the COVID-19 pandemic?. J Ultrasound
Med 2020b;, doi:http://dx.doi.org/10.1002/jum.15284.
Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified early warning
score in medical admissions. QJM 2001;94(10):521–6.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al.
Discovery, research, and development of new antibiotics: the WHO priority list
of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18
(3):318–27.
The Hastings Center. Why I Support Age-Related Rationing of Ventilators for Covid-
19 Patients [cited 2020 May 13]. Available from:. 2020. https://www.
thehastingscenter.org/why-i-support-age-related-rationing-of-ventilators-for-
covid-19-patients/.
500 P. De Nardo et al. / International Journal of Infectious Diseases 98 (2020) 494–500Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria
decision snalysis for health care decision making – an introduction: report 1 of the
ISPOR MCDA emerging good practices task force. Value Health 2016;19(1):1–13.
Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus
disease 2019 in Wuhan, China [Epub ahead of print]. Clin Infect Dis 2020;, doi:
http://dx.doi.org/10.1093/cid/ciaa272 pii:ciaa272.
White DB, Lo B. A framework for rationing ventilators and critical care beds during
the COVID-19 pandemic [Published online March 27]. JAMA 2020;, doi:http://
dx.doi.org/10.1001/jama.2020.5046.World Health Organization. Coronavirus disease (COVID-19) pandemic. Coronavirus
disease (COVID-19) pandemic – situation report. [cited 2020 May 13]. Available
from:. Geneva: WHO; 2020. https://www.who.int/emergencies/diseases/nov-
el-coronavirus-2019.
Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies
for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med 2020;8(3):
e11–2.
